Thousand Oaks, CA – According to filings with the U.S. Securities and Exchange Commission, ADRX is raising $2,575,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Madhavan Balachandran played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ADRX

ADRx is advancing drug candidates for Alzhiemer’s disease, systemic amyloidosis and ovarian cancer. The ADRx team has developed  ADvantage, a novel drug discovery technology platform that  leverages our deep understanding of amyloid protein structure, aggregation and function. ADRx has employed its ADvantage technology to design and evolve novel compounds to address unmet medical needs in amyloid diseases. ADRx is a privately funded preclinical stage biotechnology company located in Thousand Oaks, California.

To learn more about ADRX, visit http://www.adrxpharma.com/

Contact:
Madhavan Balachandran, Chief Executive Officer
805-497-2379

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved